DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, is focused on advancing innovative treatments for severe medical conditions such as preeclampsia, fetal growth restriction, and acute ischemic stroke. The company has announced that its President and CEO, Rick Pauls, will represent DiaMedica at the Jefferies Global Healthcare Conference in London, scheduled for November 17-20, 2025. During this event, Mr. Pauls will deliver a corporate presentation and engage in one-on-one meetings with investors.

The specific details for the presentation are set for Thursday, November 20, 2025, from 10:00 AM to 10:25 AM Greenwich Mean Time (GMT). This platform offers DiaMedica an opportunity to share insights into its ongoing development programs and strategic vision, particularly focusing on its lead candidate, DM199, which is a synthetic version of the KLK1 protein. DM199 represents a significant advancement as it is the first recombinant form of this protein to undergo clinical trials in the United States.

KLK1 has a well-established role in treating acute ischemic stroke and various vascular disorders in China, positioning DiaMedica’s approach as a promising avenue for medical innovation in the U.S. market. As the company actively promotes its research and development efforts, the Jefferies Global Healthcare Conference is a critical setting for attracting investor interest and broadening its visibility within the healthcare sector.

For further details, interested parties can visit DiaMedica's official website or contact their investor relations and media representatives. This participation in a prestigious healthcare conference underscores DiaMedica's commitment to tackling serious health challenges through novel therapies.

Investors should closely monitor DiaMedica Therapeutics Inc. (Nasdaq: DMAC) as the company prepares to participate in the Jefferies Global Healthcare Conference in London from November 17-20, 2025. The presence of CEO Rick Pauls at this notable conference signifies a pivotal opportunity for the company to showcase its innovative approach to treating serious medical conditions such as preeclampsia and acute ischemic stroke, specifically through its lead candidate, DM199.

DM199 is noteworthy because it represents a first-of-its-kind clinically studied recombinant form of the KLK1 protein in the United States. Given that KLK1 has already been adopted therapeutically in China for vascular diseases, the potential market for DM199 could be significant if clinical trials confirm its efficacy and safety. As the company is in the clinical stage, the upcoming corporate presentation could bring critical insights into trial progress, regulatory strategies, and potential partnerships or funding—details that may materially affect DiaMedica’s stock price.

Moreover, the timing of this event is crucial, as the market remains highly receptive to biotech advancements, particularly in the stroke intervention space. Investors should keenly analyze the key messages from the corporate presentation and any feedback gathered during one-on-one investor meetings. With the biopharmaceutical sector often characterized by high volatility, a well-executed presentation could provide a bullish catalyst leading to positive price movement.

In conclusion, while DiaMedica Therapeutics commands a clinical focus with inherent risks, its participation in the Jefferies conference presents a vital opportunity for growth potential. Investors should consider monitoring this event closely to gauge market sentiment and implications for future investment decisions.